Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Extension Trial of DELTA 1 and DELTA 2 to Evaluate the Long-term Safety of a Twice-daily Treatment With Delgocitinib Cream 20 mg/g as Needed for up to 36 Weeks in Adult Subjects With Chronic Hand Eczema (DELTA 3)

NCT04949841 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT04949841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04949841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Extension Trial of DELTA 1 and DELTA 2 to Evaluate the Long-term Safety of a Twice-daily Treatment With Delgocitinib Cream 20 mg/g as Needed for up to 36 Weeks in Adult Subjects With Chronic Hand Eczema (DELTA 3)
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 23, 2021
Completion date
September 18, 2023
Enrollment
801 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema